| scholarly article | Q13442814 |
| P2093 | author name string | Claire Colas | |
| P2860 | cites work | Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc | Q92503254 |
| Insights into the mechanism and pharmacology of neurotransmitter sodium symporters | Q92677837 | ||
| A structural model of the human serotonin transporter in an outward-occluded state | Q93103311 | ||
| Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy | Q96021443 | ||
| Molecular basis of ligand recognition and transport by glucose transporters | Q24338453 | ||
| Function of human Rh based on structure of RhCG at 2.1 A | Q24606200 | ||
| X-ray structure of dopamine transporter elucidates antidepressant mechanism | Q24612997 | ||
| Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures | Q24655640 | ||
| A Call for Systematic Research on Solute Carriers | Q26800313 | ||
| How LeuT shapes our understanding of the mechanisms of sodium-coupled neurotransmitter transporters | Q26866308 | ||
| SLC transporters as therapeutic targets: emerging opportunities | Q27014726 | ||
| A conserved leucine occupies the empty substrate site of LeuT in the Na(+)-free return state | Q27315933 | ||
| Neurotransmitter and psychostimulant recognition by the dopamine transporter | Q27316816 | ||
| The Crystal Structure of a Sodium Galactose Transporter Reveals Mechanistic Insights into Na+/Sugar Symport | Q27651031 | ||
| Molecular basis of transport and regulation in the Na(+)/betaine symporter BetP | Q27654016 | ||
| Structure and mechanism of an amino acid antiporter | Q27655670 | ||
| The mechanism of sodium and substrate release from the binding pocket of vSGLT | Q27666183 | ||
| Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling. | Q51315166 | ||
| Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth. | Q51702805 | ||
| Shared dynamics of LeuT superfamily members and allosteric differentiation by structural irregularities and multimerization. | Q55128087 | ||
| Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective | Q57176854 | ||
| The Resolution Revolution | Q57806883 | ||
| Cryo-EM structure of the human neutral amino acid transporter ASCT2 | Q57952962 | ||
| Structure activity relationship of selective GABA uptake inhibitors | Q61998271 | ||
| A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function | Q80035224 | ||
| Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2 | Q87726414 | ||
| X-ray structure of LeuT in an inward-facing occluded conformation reveals mechanism of substrate release | Q89819254 | ||
| Advances and Challenges in Rational Drug Design for SLCs | Q90099257 | ||
| Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport | Q90284315 | ||
| Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1) | Q90494434 | ||
| The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter | Q90544357 | ||
| Cryo-EM in drug discovery | Q91061978 | ||
| Monoamine transporters: structure, intrinsic dynamics and allosteric regulation | Q91595356 | ||
| The RESOLUTE consortium: unlocking SLC transporters for drug discovery | Q91709060 | ||
| Computational Dissection of Membrane Transport at a Microscopic Level | Q91781389 | ||
| Studies of structural determinants of substrate binding in the Creatine Transporter (CreaT, SLC6A8) using molecular models | Q91817101 | ||
| Structural and molecular aspects of betaine-GABA transporter 1 (BGT1) and its relation to brain function | Q92158507 | ||
| Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex | Q92342056 | ||
| Principles for Integrative Structural Biology Studies | Q92442130 | ||
| An Extra Amino Acid Residue in Transmembrane Domain 10 of the γ-Aminobutyric Acid (GABA) Transporter GAT-1 Is Required for Efficient Ion-coupled Transport. | Q38954548 | ||
| Transport of gabapentin by LAT1 (SLC7A5). | Q39169276 | ||
| Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. | Q39615238 | ||
| Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter | Q40390385 | ||
| SLC classification: an update | Q42082729 | ||
| LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates | Q42221833 | ||
| Structure and allosteric inhibition of excitatory amino acid transporter 1. | Q42356946 | ||
| State-dependent conformations of the translocation pathway in the tyrosine transporter Tyt1, a novel neurotransmitter:sodium symporter from Fusobacterium nucleatum. | Q42689431 | ||
| The mechanism of a neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by substrate in a second binding site | Q42909481 | ||
| High- and low-affinity transport of L-leucine and L-DOPA by the hetero amino acid exchangers LAT1 and LAT2 in LLC-PK1 renal cells. | Q44991379 | ||
| Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine. | Q45951082 | ||
| Ligand Binding in the Extracellular Vestibule of the Neurotransmitter Transporter Homologue LeuT. | Q46311667 | ||
| Large neutral amino acid transporter enables brain drug delivery via prodrugs | Q46793172 | ||
| Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1. | Q47431439 | ||
| Cholesterol binding to a conserved site modulates conformation, pharmacology and transport kinetics of the human serotonin transporter. | Q47651388 | ||
| Structure-Activity Relationship, Pharmacological Characterization, and Molecular Modeling of Noncompetitive Inhibitors of the Betaine/γ-Aminobutyric Acid Transporter 1 (BGT1). | Q47677927 | ||
| Ligand Selectivity among the Dopamine and Serotonin Transporters Specified by the Forward Binding Reaction | Q47721135 | ||
| LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier? | Q48148305 | ||
| L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs | Q48219241 | ||
| A direct interaction of cholesterol with the dopamine transporter prevents its out-to-inward transition | Q48253036 | ||
| Molecular Determinants for Substrate Interactions with the Glycine Transporter GlyT2. | Q48334358 | ||
| Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system. | Q48369130 | ||
| A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells. | Q48699850 | ||
| The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. | Q48953363 | ||
| The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. | Q49095555 | ||
| Structural basis for recognition of diverse antidepressants by the human serotonin transporter. | Q49594975 | ||
| X-ray structures of LeuT in substrate-free outward-open and apo inward-open states | Q27676655 | ||
| Alternating-access mechanism in conformationally asymmetric trimers of the betaine transporter BetP | Q27682108 | ||
| Crystal structure of the human glucose transporter GLUT1 | Q27690274 | ||
| Crystal structure of the anion exchanger domain of human erythrocyte band 3 | Q27702576 | ||
| Neurotransmitter transporters: molecular function of important drug targets | Q28244986 | ||
| Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay | Q28830248 | ||
| Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters | Q29616590 | ||
| Membrane transporters in drug development | Q29616802 | ||
| Substrate binding and formation of an occluded state in the leucine transporter | Q30481294 | ||
| A mechanism for intracellular release of Na+ by neurotransmitter/sodium symporters | Q30623808 | ||
| The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter | Q33813126 | ||
| Structural Symmetry in Membrane Proteins. | Q33880058 | ||
| The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. | Q33919682 | ||
| X-ray structures and mechanism of the human serotonin transporter | Q34521033 | ||
| Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells | Q34835751 | ||
| The rocking bundle: a mechanism for ion-coupled solute flux by symmetrical transporters. | Q35016767 | ||
| Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters | Q35123142 | ||
| X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine | Q36170340 | ||
| The solute carrier 6 family of transporters | Q36346899 | ||
| Stereoselective uptake of beta-lactam antibiotics by the intestinal peptide transporter | Q36804889 | ||
| LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs | Q36923089 | ||
| Membrane proteins: molecular dynamics simulations. | Q37136274 | ||
| Insights into the molecular basis for substrate binding and specificity of the wild-type L-arginine/agmatine antiporter AdiC. | Q37264231 | ||
| SLC Transporters: Structure, Function, and Drug Discovery. | Q37279747 | ||
| Structure and function of Na(+)-symporters with inverted repeats | Q37561881 | ||
| Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram | Q37579976 | ||
| The structural basis of secondary active transport mechanisms. | Q37804492 | ||
| SLC6 neurotransmitter transporters: structure, function, and regulation | Q37900787 | ||
| The SLC3 and SLC7 families of amino acid transporters | Q38090767 | ||
| Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics | Q38476583 | ||
| To be, or not to be two sites: that is the question about LeuT substrate binding | Q38586753 | ||
| Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1). | Q38714635 | ||
| Shared Molecular Mechanisms of Membrane Transporters | Q38792631 | ||
| Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. | Q38921284 | ||
| L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors | Q38928020 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 1229 | |
| P577 | publication date | 2020-08-19 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Toward a Systematic Structural and Functional Annotation of Solute Carriers Transporters-Example of the SLC6 and SLC7 Families | |
| P478 | volume | 11 |
Search more.